Navigation Links
Bevacizumab found to improve survival for patients with advanced breast cancer
Date:12/26/2007

Inhibiting the growth of blood vessels that supply tumors slows the progression of metastatic breast cancer according to results of a large clinical trial of Avastin, an anti-angiogenic therapy. The study, published in the December 27th issue of the New England Journal of Medicine, found that Avastin in combination with chemotherapy significantly prolongs progression-free survival for women with breast cancer compared to chemotherapy alone.

Rush University Medical Center participated in the clinical trial which was sponsored by the National Cancer Institute and conducted by a network of researchers led by the Eastern Cooperative Oncology Group (ECOG).

The study of 722 women with recurrent (metastatic) breast cancer found that the women who received Avastin in combination with standard chemotherapy had a doubling of delay in worsening of their cancer by approximately five months, on average, compared to patients treated with chemotherapy alone. Those on Avastin had progression-free survival of 11.3 months compared to 6 months on standard chemotherapy alone.

"This therapy is a one-two punch! You hit the tumor with the chemo and sabotage new blood vessel growth by restricting its oxygen supply with Avastin," said Dr. Melody Cobleigh, co-author of the study and director of the Coleman Foundation Comprehensive Breast Center at Rush. "This is a noteworthy advance in cancer treatment."

Avastin is a therapeutic antibody designed to specifically inhibit vascular endothelial growth factor (VEGF), a protein that plays an important role in angiogenesis and the maintenance of existing blood vessels throughout the lifecycle of a tumor. By inhibiting VEGF, Avastin is designed to interfere with the blood supply to a tumor, which is thought to be critical to a tumors ability to grow and spread in the body.

Avastin not only slowed the growth of the tumor, it also doubled the remission rate (the shrinkage of tumors by 50 percent or more) compared with chemotherapy alone. With chemotherapy, 25% of tumors responded; with the combination of chemotherapy and bevacizumab, 49% did so.

Rush University Medical Center has been involved in the study of Avastin from the very beginning, participating in the Phase I, Phase II and Phase III studies of the drug. The next step is studying the drug in the adjuvant setting to determine if it can help decrease the risk of cancer recurrence.

"The tumor cant grow bigger than the size of a sesame seed without an oxygen supply," said Cobleigh. "And patients can stay on Avastin as long at it works. It is not a chemotherapy drug so it has minimal toxicity. "

According to the American Cancer Society, an estimated 178,000 women will be diagnosed with breast cancer and approximately 40,000 will die from the disease in the United States in 2007.


'/>"/>

Contact: Kim Waterman
Kimberly_Waterman@rush.edu
312-942-7820
Rush University Medical Center
Source:Eurekalert

Related medicine news :

1. One Species Genome Found Within Another
2. National Patient Safety Foundation Partners with Vocera Communications
3. R. P. Simmons Family Foundation Pledges $2 Million for New Childrens Hospital of Pittsburgh of UPMC Campus
4. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
5. AIDS Healthcare Foundation Applauds City Commissioners Support of Diversity, Urges Call for Mayors Resignation
6. National Osteoporosis Foundation Teams Up With Ladies Home Journal Magazine to Launch a 10-city Mall Walk Tour
7. Judge Rules That Florida Disease Management Program Serving 8,000 HIV/AIDS Patients Should Be Re-bid, Says AIDS Healthcare Foundation
8. The Tug McGraw Foundation Announces 2007 Fundraising Gala
9. The Arthur M. Blank Family Foundation Pushes for Pre-K Expansion in Georgia
10. Cipla, Tell the Truth; AIDS Healthcare Foundation Launches New Ad Campaign
11. Big Relief for Tiny Itch Mites Found in All Natural Spray Remedy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2017)... ONTARIO, CANADA (PRWEB) , ... July 22, 2017 ... ... can offer patients with irreparable rotator cuff repairs the opportunity to return to ... at the American Orthopaedic Society for Sports Medicine’s Annual Meeting in ...
(Date:7/21/2017)... ... July 21, 2017 , ... Roderick Crabbe Insurance, ... to families and business owners in northern Florida, is joining the First Coast ... to area adults with developmental challenges. , The First Coast YMCA offers assistance ...
(Date:7/21/2017)... Connecticut (PRWEB) , ... July 21, 2017 , ... Hospital ... from HealthCareMandA.com . The number of hospital acquisitions rose to 23 in the ... of 2017, and up 15% from the 20 announced deals in the year-ago second ...
(Date:7/21/2017)... ... 21, 2017 , ... MedMatchPlus+ has launched a residency application ... a residency in a United States hospital. Being accepted into a residency is ... to data released by the ECFMG®, every year, 50 percent of international medical ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... (ACL) offer patients improved quality of life five years after injury, according to ... Annual Meeting in Toronto, Ontario, Canada. The study followed patients for five years ...
Breaking Medicine News(10 mins):
(Date:7/14/2017)... July 13, 2017 It should come as no ... is in the midst of a crippling opioid epidemic. ... 1999, the number of overdose deaths from opiate-based medications has ... half a million dead from 2001 to 2015". During this ... hydrocodone has similarly quadrupled, drawing a compelling link between prescription ...
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)...  Dr. Echenberg, founder of Echenberg Institute, is announcing a new safe ... from painful intercourse and other painful pelvic pain conditions such as pelvic ... ... ... Florida -based start-up company, VuVatech LLC, fills a void in the ...
Breaking Medicine Technology: